Event-related brain potentials and working memory function in healthy humans after single-dose and prolonged intranasal administration of adrenocorticotropin 4-10 and desacetyl-α- melanocyte stimulating hormone

Journal of Clinical Psychopharmacology

Volumn 20, Issue 4, 2000, Pages 445-454

  Smolnik, Rüdiger ^a   Perras, Boris ^a   Mölle, Matthias ^a   Fehm, Horst Lorenz ^a   Born, Jan ^a,b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF BAMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN DERIVATIVE; CORTICOTROPIN[4-10];

ADULT; ALERTNESS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; EVENT RELATED POTENTIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMISSION; PRIORITY JOURNAL; REACTION TIME; WORKING MEMORY;

ADMINISTRATION, INTRANASAL; ADRENOCORTICOTROPIC HORMONE; ADULT; AFFECT; ALPHA-MSH; AROUSAL; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; PSYCHOMOTOR PERFORMANCE;

EID: 0033927739     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200008000-00009     Document Type: Article

References (47)

1. de Wied D. Neurotrophic effects of ACTH/MSH neuropeptides. Acta Neurobiol Exp (Warsz) 1990;50:353-66.
2. Beckwith BE, Sandman CA. Central nervous system and peripheral effects of ACTH, MSH, and related neuropeptides. Peptides 1982;3:411-20.
3. Born J, Fehm HL, Voigt KH. ACTH and attention in humans: a review. Neuropsychobiology 1986;15:165-86.
4. Born J, Bräuninger W, Fehm-Wolfsdorf G, Voigt KH, Pauschinger P, Fehm HL. Dose-dependent influences on electrophysiological signs of attention in humans after neuropeptide ACTH 4-10. Exp Brain Res 1987;67:85-92.
5. Born J, Unseld U, Pietrowsky R, Bickel U, Voigt KH, Fehm HL. Time course of ACTH 4-10 effects on human attention. Neuroendocrinology 1990;52:169-74.
6. Donchin E. Surprise! . . . Surprise? Psychophysiology 1981;18: 493-513.
7. Donchin E, Coles MGH. Is the P300 component a manifestation of context updating? Behav Brain Sci 1988;11:357-74.
8. Verleger R. Event-related potentials and cognition: a critique of the context updating hypothesis and an alternative interpretation of the P3. Behav Brain Sci 1988;11:343-56.
9. Rockstroh B, Elbert T, Lutzenberger W, Birbaumer N, Voigt KH, Fehm HL. Distractability under the influence of an ACTH 4-9 derivative. Int J Neurosci 1983;22:21-36.
10. Fabiani M, Karis D, Donchin E. P300 and recall in an incidental memory paradigm. Psychophysiology 1986;23:298-308.
11. Fabiani M, Karis D, Donchin E. Effects of mnemonic strategy manipulation in a Von Restorff paradigm. Electroencephalogr Clin Neurophysiol 1990;75:22-35.
12. Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 1999;48:557-63.
13. Miller LH, Harris LC, Van Riezen H, Kastin AJ. Neuroheptapeptide influence on attention and memory in man. Pharmacol Biochem Behav 1976;5:17-21.
14. Veith JL, Sandman CA, George JM, Stevens VC. Effects of MSH/ ACTH 4-10 on memory, attention and endogenous hormone levels in women. Physiol Behav 1978;20:43-50.
15. Dornbush RL, Nikolovski O. ACTH 4-10 and short-term memory. Pharmacol Biochem Behav 1976;5:69-72.
16. Gaillard AW, Varey CA. Some effects of an ACTH 4-9 analog (Org 2766) on human performance. Physiol Behav 1979;23:79-84.
17. Ferris SH, Reisberg B, Gershon S. Neuropeptide effects on cognition in the elderly. In: Poon LW, ed. Aging in the 1980s: psychological issues. Washington, DC: American Psychological Association, 1980:216-7.
18. Reul JM, Tonnaer JA, De Kloet ER. Neurotrophic ACTH analogue promotes plasticity of type I corticosteroid receptor in brain of senescent male rats. Neurobiol Aging 1988;9:253-60.
19. Balin BJ, Broadwell RD, Salcman M, El-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 1986; 251:260-80.
20. Riekkinen P, Legros JJ, Sennef C, Jolkkonen J, Smitz S, Soininen H. Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects. Peptides 1987;8:261-5.
21. Pietrowsky R, Strüben C, Mölle M, Fehm HL, Born J. Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans. Biol Psychiatry 1996;39:332-10.
22. Pietrowsky R, Thiemann A, Kern W, Fehm HL, Born J. A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin. Psychoneuroendocrinology 1996;21:559-72.
23. Kern W, Schiefer B, Schwarzenberg J, Stange EF, Born J, Fehm HL. Evidence for central nervous effects of corticotropin-releasing hormone on gastric acid secretion in humans. Neuroendocrinology 1997;65:291-8.
24. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of genes that encode the melanocortin receptors. Science 1992;257: 1248-51.
25. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, DelValle J, Yamada T. Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993;268:8246-50.
26. Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, Entwistle ML, Simerly RB, Cone RD. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci U S A 1993;90:8856-60.
27. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, DelValle J, Yamada T. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993;268: 15174-9.
28. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994;8:1298-308.
29. Chhajlani V, Muceniece R, Wikberg JES. Molecular cloning of a novel human melanocortin receptor. Biochem Biophys Res Commun 1993;195:866-73.
30. Desarnaud F, Labbe O, Eggerickx D, Vassart G, Parmentier M. Molecular cloning, functional expression and pharmacological characterization of a mouse melanocortin receptor gene. Biochem J 1994;299:367-73.
31. Gantz I, Shimoto Y, Konda Y, Miwa H, Dickinson CJ, Yamada T. Molecular cloning, expression, and characterization of a fifth melanocortin receptor. Biochem Biophys Res Commun 1994;200: 1214-20.
32. Janke W, Debus G. Die Eigenschaftswörterliste[em]EWL. Göttingen: Hogrefe, 1978.
33. Näätänen R, Picton T. The N1 wave of the human electric and magnetic response to sound: a review and an analysis of the component structure. Psychophysiology 1987;24:375-425.
34. Bickel U, Born J, Fehm HL, Distler M, Voigt KH. The behaviorally active peptide ACTH 4-10: measurement in plasma and pharmacokinetics in man. Eur J Pharmacol 1988;35:371-7.
35. Hussain MA, Seetharam R, Wilk RR, Aungst BJ, Kettner CA. Nasal mucosal metabolism and absorption of pentapeptide enkephalin analogs having varying N-terminal amino acids. J Pharm Sci 1995;84:62-4.
36. Burbach JP, Lebouille JLM, Wang XC. Metabolic conversion of pro-opiomelanocortin peptides by brain peptidases: ACTH, α-MSH, β-endorphin. In: de Wied D, Ferrari W, eds. Central actions of ACTH and related peptides. Fida Research Series, Symposia in Neuroscience IV. Padova: Liviana Press, 1986:53-67.
37. Ruchkin DS, Sutton S, Stega M. Emitted P300 and slow wave event-related potentials in guessing and detection tasks. Electroencephalogr Clin Neurophysiol 1980;49:1-14.
38. Roth WT, Ford JM, Kopell BS. Long-latency evoked potentials and reaction time. Psychophysiology 1978;15:17-23.
39. Ruchkin DS, Sutton S, Kietzman ML, Silver K. Slow wave and P300 in signal detection. Electroencephalogr Clin Neurophysiol 1980; 50:35-47.
40. Mölle M, Pietrowsky R, Fehm HL, Born J. Regulation of human thought by neuropeptide ACTH 4-10: an analysis of the EEG's dimensional complexity. Neuroreport 1997;8:2715-20.
41. Roth WT, Pfefferbaum A, Kelly AF, Berger PA, Kopell BS. Auditory event-related potentials in schizophrenia and depression. Psychiatry Res 1981;4:199-212.
42. Ogura C, Nageishi Y, Matsubayashi M, Omura F, Kishimoto A, Shimokochi M. Abnormalities in event-related potentials, N100, P200, P300 and slow wave in schizophrenia. Jpn J Psychiatry Neurol 1991;45:57-65.
43. Ward PB, Catts SV, Fox AM, Michie PT, McConaghy N. Auditory selective attention and event-related potentials in schizophrenia. Br J Psychiatry 1991;158:534-9.
44. Hirayasu Y, Asato N, Ohta H, Hokama H, Arakaki H, Ogura C. Abnormalities of auditory event-related potentials in schizophrenia prior to treatment. Biol Psychiatry 1998;43:244-53.
45. Smolnik R, Mölle M, Fehm HL, Born J. Brain potentials and attention after acute and subchronic intranasal administration of ACTH 4-10 and desacetyl-α-MSH in humans. Neuroendocrinology 1999;70:63-72.
46. Adan RAH, Cone RD, Burbach JPH, Gispen WH. Differential effects of melanocortin peptides on neural melanocortin receptors. Mol Pharmacol 1994;46:1182-90.
47. van Rijzingen IM, Gispen WH, Spruijt BM. The ACTH(4-9) analog ORG 2766 and recovery after brain damage in animal models - a review. Behav Brain Res 1996;74:1-15.